Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 4—April 2014
Research

Epidemic of Mumps among Vaccinated Persons, the Netherlands, 2009–2012

Jussi SaneComments to Author , Sigrid Gouma, Marion Koopmans, Hester de Melker, Corien Swaan, Rob van Binnendijk, and Susan Hahné
Author affiliations: National Institute for Public Health and the Environment, Bilthoven, the Netherlands (J. Sane, S. Gouma, M. Koopmans, H. de Melker, C. Swaan, R. van Binnendijk, S. Hahné); European Programme for Intervention Epidemiology Training, European Centre for Disease Prevention and Control, Stockholm, Sweden (J. Sane); Erasmus Medical Centre, Rotterdam, the Netherlands (S. Gouma, M. Koopmans)

Main Article

Table 1

Association between rates of mumps complications and hospitalization and MMR status, the Netherlands, September 1, 2009–August 31, 2012*

Complication No. MMR doses received by case-patient No. (%) case-patients with complications Crude OR (95% CI) p value aOR† (95%CI) p value aVE† (95% CI)
Orchitis§ 0 36 (15.5) Ref Ref Ref Ref
1 10 (6.6) 0.46 (0.22–0.97) 0.04 0.46 (0.22–0.98) 0.04 54 (2–78)
2 46 (4.7) 0.26 (0.16–0.41) <0.01 0.26 (0.15–0.43) <0.01 74 (57–85)
Deafness 0 2 (0.9) Ref
1 0 NA NA – – –
2 1 (0.1) 0.12 (0.01–1.3) 0.1 – – –
Meningitis 0 2 (0.8) Ref
1 1 (0.6) 0.76 (0.07–8.5) 0.8 – – –
2 2 (0.2) 0.24 (0.03–1.7) 0.2 – – –
All complications 0 44 (19.0) Ref Ref Ref Ref
1 10 (6.6) 0.30 (0.15–0.62) <0.01 0.29 (0.14–0.62) <0.01 71 (38–86)
2 55 (5.7) 0.26 (0.17–0.39) <0.01 0.24 (0.14–0.39) <0.01 76 (61–86)
Hospitalization 0 11 (4.8) Ref Ref Ref Ref
1 3 (2.0) 0.41 (0.11–1.5) 0.18 0.43 (0.11–1.6) 0.2 57 (–60 to 89)
2 10 (1.1) 0.22 (0.09–0.52) <0.01 0.18 (0.07–0.47) <0.01 82 (53–93)

*Only case-patients with known complications and vaccination status were included in the analyses. OR, odds ratio; VE, vaccine effectiveness; Ref, referent; NA, not applicable; –, not analyzed (insufficient sample size).
†Adjusted for age (age groups <18 y, 18–25 y, >25 y) and sex, except orchitis, which was adjusted only for age.
§Includes only male case-patients >12 y of age.

Main Article

Page created: March 12, 2014
Page updated: March 12, 2014
Page reviewed: March 12, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external